| Budget Amount *help |
¥17,680,000 (Direct Cost: ¥13,600,000、Indirect Cost: ¥4,080,000)
Fiscal Year 2022: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
Fiscal Year 2021: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2020: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
Since cancer cells become radioresistant under hypoxic conditions and cause poor patient prognosis, there is a need to monitor tumor hypoxia differently in each patient and to establish therapies that target tumor hypoxia. In this study, we identified SPINK1 as a protein secreted by hypoxia-stimulated cancer cells and found that its plasma concentration can be used to monitor the hypoxic fraction in tumors, and that inhibition of SPINK1 can enhance therapeutic effect of radiation.
|
